These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 10705891)

  • 1. Gatifloxacin and moxifloxacin: two new fluoroquinolones.
    Med Lett Drugs Ther; 2000 Feb; 42(1072):15-7. PubMed ID: 10705891
    [No Abstract]   [Full Text] [Related]  

  • 2. Moxifloxacin for community-acquired pneumonia.
    Rijnders BJ
    Antimicrob Agents Chemother; 2003 Jan; 47(1):444; author reply 444-5. PubMed ID: 12499236
    [No Abstract]   [Full Text] [Related]  

  • 3. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
    Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
    Talan DA
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
    Lister PD
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S33-8. PubMed ID: 11249827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving care for patients with respiratory tract infections.
    Lode H; Garau J
    J Chemother; 2002 Feb; 14 Suppl 2():22-8. PubMed ID: 12003137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Playing it safe in bronchopulmonary infections].
    MMW Fortschr Med; 2003 May; 145(18):57. PubMed ID: 12838909
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Staphylococcus aureus endocarditis using moxifloxacin.
    Berrington AW; Koerner RJ; Perry JD; Bain HH; Gould FK
    Int J Med Microbiol; 2001 Aug; 291(3):237-9. PubMed ID: 11554565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bactericidal activity of moxifloxacin against Staphylococcus aureus.
    Berrington AW; Perry JD; Gould FK
    Clin Microbiol Infect; 2001 Mar; 7(3):161-3. PubMed ID: 11318816
    [No Abstract]   [Full Text] [Related]  

  • 11. Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency.
    Ball P
    Int J Clin Pract; 2000 Jun; 54(5):329-32. PubMed ID: 10954961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species.
    Miyashita N; Fukano H; Yoshida K; Niki Y; Matsushima T
    J Infect Chemother; 2002 Mar; 8(1):115-7. PubMed ID: 11957133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin (Avelox) for the treatment of bacterial skin infections.
    Parish LC; Witkowski JA; Routh HB
    Skin Therapy Lett; 2001 Oct; 6(11):1-2. PubMed ID: 11719825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.
    Kim DH; Stark WJ; O'Brien TP; Dick JD
    Ophthalmology; 2005 Nov; 112(11):1992-6. PubMed ID: 16183125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional dogma applied to quinolones? Time for a change.
    Jones RN
    J Antimicrob Chemother; 2001 Jun; 47(6):893. PubMed ID: 11389126
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia.
    Torres A; Muir JF; Corris P; Kubin R; Duprat-Lomon I; Sagnier PP; Höffken G
    Eur Respir J; 2003 Jan; 21(1):135-43. PubMed ID: 12570122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of amoxicillin, gentamicin, and moxifloxacin on the hemolytic activity of Staphylococcus aureus in vitro and in vivo.
    Worlitzsch D; Kaygin H; Steinhuber A; Dalhoff A; Botzenhart K; Döring G
    Antimicrob Agents Chemother; 2001 Jan; 45(1):196-202. PubMed ID: 11120965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Moxifloxacin].
    Caballero E; Cárdenas E; Gurucharri N; Rodrigo A; Honorato J
    Rev Med Univ Navarra; 2000; 44(4):53-60. PubMed ID: 11341057
    [No Abstract]   [Full Text] [Related]  

  • 19. [Moxifloxacin: results of clinical use].
    Iakovlev VP; Polushkina NR
    Antibiot Khimioter; 2002; 47(10):32-6. PubMed ID: 12674792
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin.
    Landen H; Möller M; Tillotson GS; Kubin R; Höffken G
    J Int Med Res; 2001; 29(2):51-60. PubMed ID: 11393349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.